ProCE Banner Activity

Phase I/II Study: Belantamab Mafodotin With Lenalidomide + Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Slideset Download
Conference Coverage
Belantamab mafodotin appears to be safe, with a manageable ocular safety profile, when given with lenalidomide and dexamethasone in transplant-ineligible NDMM.

Released: December 16, 2021

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo Inc

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation